<DOC>
	<DOCNO>NCT00593554</DOCNO>
	<brief_summary>The purpose study determine haplotype-mismatched HSCT associate improvement treatment-related mortality ( TRM ) rate 6 month .</brief_summary>
	<brief_title>Phase 2 Haplotype Mismatched HSCT Patients With Hematological Malignancies</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Thiotepa</mesh_term>
	<mesh_term>Antilymphocyte Serum</mesh_term>
	<criteria>Patients must histologically document AML , ALL , MDS , CML , Acute myeloid leukemia ( AML ) one follow criterion CR 1 poor risk feature CR 2 , high order CR Acute lymphoblastic leukemia ( ALL ) one follow criterion CR 1 poor risk feature CR 2 , high order CR Myelodysplasia , RAEB I Donor identify Age â‰¤ 65 year . Performance Status 01 . Patients relapse &lt; 6 month autologous SCT eligible . Patients active infection require oral intravenous antibiotic eligible enrollment resolution infection . Nonpregnant nonnursing</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>